Business
Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries
CHICAGO, March 17, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer.
About this update from Tempus Ai, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/714c552860992d71888f83abdc4e2693"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/03ShD.e_nEprq2Njd6Kzxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/714c552860992d71888f83abdc4e2693","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/MWBVyZg.uz7uvcEMxb_9Dw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/714c552860992d71888f83abdc4e2693","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CHICAGO, March 17, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer.","length":507,"tagName":"p"},{"type":"text","content":"Part of the Blood Cancer United Dare to Dream Project, the collaboration serves a dual purpose: empowering patients with their health-related data and information relevant to their journey and fueling broader scientific breakthroughs.","length":234,"tagName":"p"},{"type":"text","content":"The collaboration will leverage olivia, Tempus’ AI-enabled personal health concierge app that centralizes health data into a single platform and uses AI to make that information accessible, actionable, and meaningful. Patients participating will receive access to olivia, which will provide tailored materials that utilize Blood Cancer United’s library of educational and patient support and access resources. Materials will be aligned to their disease subtype, treatment stage, and care needs - delivering timely, relevant information throughout their journey. olivia will also enable the collection of longitudinal electronic patient-reported outcomes and questionnaire data to inform and strengthen the registry.","length":715,"tagName":"p"},{"type":"text","content":"ol...